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Abstract 
Hereditary bleeding and platelet disorders (BPDs) are characterised by marked 
genetic heterogeneity, far greater than previously appreciated. The list of genes 
involved in the regulation of megakaryopoiesis, platelet formation, platelet function 
and bleeding has been growing rapidly since the introduction of high-throughput 
sequencing (HTS) approaches in research. Thanks to the gradual adoption of HTS 
in diagnostic practice, these discoveries are improving the diagnostic yield for BPD 
patients, who may or may not present with bleeding problems and often have other 
clinical symptoms unrelated to the blood system. However, it was previously found 
that screening for all known aetiologies gives a diagnostic yield of over 90% when 
the phenotype closely matches a known BPD but drops to 10% when the 
phenotype is indicative of a novel disorder. Thus, further research is needed to 
identify currently unknown aetiologies for BPDs. Novel genes are likely to be found 
to be implicated in BPDs. New modes of inheritance, including digenic inheritance, 
are likely to play a role in some cases. Additionally, identifying and interpreting 
pathogenic variants outside exons is a looming challenge that can only be tackled 
with an improved understanding of the regulatory landscape of relevant cell types 
and with the transition from targeted sequencing to whole-genome sequencing in 
the clinic. 
 
Overview of bleeding and platelet disorders 
Hereditary bleeding and platelet disorders (BPDs) are a heterogeneous set of 
diseases affecting approximately 3 million people worldwide. The most common 
inherited bleeding disorders are von Willebrand disease (VWD), with a prevalence of 
1 in 100 to 1,000 people, and haemophilia A, which affects 1 in 5,000 to 10,000 
males at birth. Other BPDs are globally very rare, with some having been described 
in fewer than five unrelated families worldwide, although certain disorders have an 
elevated prevalence in specific subpopulations due to founder effects. Over the 
past five decades, the genetic bases of some of these disorders have been 
identified. Most of the genes harbouring variants responsible for BPDs (henceforth, 
BPD genes) have been identified through linkage studies across informative 
pedigrees or using candidate gene Sanger sequencing following thorough clinical 
and laboratory work-up. However, over the last decade, high-throughput 
sequencing (HTS) has become the primary means of identifying genetic variants and 
experimental designs have expanded to include case/control comparisons. 
 
BPDs may be categorised into coagulation defects and platelet defects. Table 1 
lists bleeding disorders due to defects in 21 genes that regulate the coagulation 
pathways and platelet disorders due to defects in 52 genes important for platelet 
formation, morphology or function. In this review, we do not describe these 
diseases in detail and instead refer the reader to other recent reviews of BPDs [1], 
[2], [3], [4]. 
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As the catalogue of known BPD genes has expanded and the cost of HTS has 
decreased, it has become apparent that Sanger-based sequencing of specific 
genes suspected of harbouring pathogenic variants in particular patients is, in many 
situations, a slower, more expensive and less sensitive means of facilitating a 
molecular diagnosis than HTS of many genes at a time. Sanger-based approaches 
are particularly ill-suited for the diagnosis of diseases that are genetically 
heterogeneous but for which a molecular diagnosis would help assess the risk of 
specific comorbidities. For example, thrombocytopenia may have a concomitant 
increase in the risk of leukaemia and Hermansky-Pudlak syndrome may have a 
concomitant increase in the risk of lung fibrosis, depending on the specific variants 
responsible. In these cases, a molecular diagnosis is required in order to identify 
such increased risks of developing life-threatening conditions. Furthermore, 
assaying a large panel of genes during sequencing reduces the need for some of 
the painstaking assays typically required to narrow down the set of potential 
aetiologies needed to select appropriate genes for Sanger sequencing. In due 
course, genetic testing will not be postponed until specialised tests such as light 
transmission aggregometry have been performed, and this will simplify and hasten 
the overall diagnostic process [5]. 
 
Currently, HTS is used in both research and clinical settings, and there is a rapid 
translation of emerging findings into diagnostic practice. HTS can be applied to the 
whole or only to selected parts of the genome. Whole-genome sequencing (WGS) is 
the simplest approach and involves indiscriminate sequencing of DNA from lysed 
cells. The other approach is targeted sequencing of pre-specified regions of the 
genome. Whole-exome sequencing (WES) targets all or virtually all exons from all 
genes while panel-based sequencing targets only the regions of the genome 
relevant to a particular disease area and may include non-coding regions not 
covered by typical WES platforms. Panel-based assays are typically designed 
specifically so that clinical-grade accuracy can be achieved at virtually all genomic 
bases of interest, while WES platforms tend to cover a larger proportion of targeted 
regions poorly due to technical biases. Compared to WGS, all targeted methods 
require additional steps in the library preparation protocol and the design and 
purchase of assays for performing enrichment, typically microarrays. On the other 
hand, they reduce the amount of sequencing per patient required to achieve 
accurate variant calling in the parts of the genome thought to be relevant to a 
disease area. Thus, the advantage of targeted sequencing over WGS is purely 
economic. As sequencing costs continue to decline, targeted sequencing will 
foreseeably be replaced universally by WGS. 
 
Platforms for targeted DNA sequencing 
The first approaches for targeted DNA sequencing of known BPD genes have 
recently been initiated by the ThromboGenomics and UK Genotyping and 
Phenotyping of Platelets (UK-GAPP) consortia. The ThromboGenomics consortium 
reported on a targeted HTS panel of 76 genes (in the published version) for the 
diagnosis of inherited thrombotic and BPDs [6] and has thus far processed over 
2,000 patient samples (personal communication). Initial testing of about 300 
patients showed 100% sensitivity to detect previously identified causal variants 
based on 159 patients. When the phenotype was strongly indicative of a particular 
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disease aetiology but the variants were unknown, diagnostic sensitivity was also 
high, at >90% based on 61 patients. However, for patients without a recognisable 
hereditary disorder (e.g. those with delta storage pool disease or bleeding with 
normal platelet and coagulation test results), a genetic diagnosis was only possible 
in 10% of cases. Such BPD patients should be included in research programmes, 
as we describe below. The published version of the ThromboGenomics platform 
has already undergone a revision because novel BPD genes have since been 
discovered through HTS-based discovery programmes (e.g. DIAPH1, SRC, FYB). 
However, clinical reporting on any new genes must await their approval for so-
called “Tier 1” status. These are genes for which there is substantial evidence that 
variants therein are implicated in BPDs. Generally, causal variants need to have 
been identified in at least three unrelated pedigrees with similar phenotypes or in a 
very large pedigree with strong evidence from co-segregation studies, supported by 
experimental evidence from a mouse model. Formally, the decision to include a 
gene to the Tier 1 list is made by the Scientific and Standardization Committee 
(SSC) on “Genomics in Thrombosis and Haemostasis (GinTH)” of the International 
Society on Thrombosis and Haemostasis (ISTH). 
 
The UK-GAPP study reported its first findings in 2012 using a targeted panel of 216 
genes that included genes with hypothetical roles in BPDs [7]. More recently, the 
UK-GAPP used WES to analyse 329 potential candidate BPD genes in 18 unrelated 
index patients with Gi signaling or secretion defects [8]. Although the performance 
and details of other targeted platforms have not yet been published, one that 
includes 71 platelet-related genes has been developed by a Spanish team and used 
in a published case study [9], [10]. In addition, a team from Denmark is using WES 
with subsequent analysis of 87 genes related to bleeding, thrombocytopenia and 
thrombocytopathia, as presented at last year’s American Society of Hematology 
meeting [11]. Their approach evaluates several genes implicated in Ehlers Danlos 
syndrome (COL3A1, COL5A2, COL5A1) but does not include all coagulation genes. 
Lastly, a team in Germany has developed a platform to target the entire F8 gene in 
order to detect deep intronic variants that are typically missed by WES [12], an 
approach also incorporated into the revised ThromboGenomics platform primarily 
to identify the recurrent intron 22 inversion. 
 
Approaches to patient phenotyping 
Aggregating genetic and phenotypic patient data is essential to obtain the statistical 
power required to identify the genetic defects responsible for rare disorders. Data 
sharing is also important to enable a better understanding of the phenotypic 
heterogeneity of rare disorders. A standardised method of phenotyping is therefore 
key for these analyses and also for entering data into and interchanging data 
between clinical registries, genotype-phenotype databases and biobanks. The two 
most widely used clinical coding systems are ICD10 (the World Health 
Organisation's International Classification of Diseases version 10, 
http://www.who.int/classifications/icd) and SNOMED-CT (Systematized 
Nomenclature of Medicine Clinical Terminology, http://www.ihtsdo.org). These 
systems are primarily aimed at codifying diagnoses rather than describing 
phenotypes and lack the flexibility required to describe novel rare inherited 
disorders. For example, they would not have been capable of capturing dominant 
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myelofibrosis with mild thrombocytopenia and bone defects, which we recently 
found to be caused by a germline gain-of-function variant in SRC [13]. Thus, ICD10 
and SNOWMED-CT in their current forms are not well suited for rare disease 
research and diagnostics and their use could hamper data-sharing efforts. Instead, 
researchers and clinicians have opted for structured phenotype vocabularies called 
ontologies to describe rare diseases and their manifestations in particular patients. 
A phenotype ontology is a catalogue of specific signs, symptoms or laboratory 
findings seen in the clinic. Individual items (e.g. thrombocytopenia or abnormal APD 
aggregation) are referred to as terms with optional definitions, synonyms and 
translations. Additionally, ontologies provide hierarchical relations between the 
terms, which may range from the very specific to the general. While disease 
ontologies contain terms for known diseases such as Hermansky Pudlack 
syndrome (HPS), phenotype ontologies contain terms for individual manifestations 
of diseases, which in the case of HPS might include Ocular albinism, Abnormal ATP 
secretion and Abnormal bleeding. The Human Phenotype Ontology (HPO) was 
developed for the annotation of phenotypic abnormalities [14], [15] and is available 
under an open-source licence (http://www.human-phenotype-ontology.org). The 
general term that is most pertinent to BPDs is Abnormality of blood and blood-
forming tissues and has the following HPO subclasses, among others: Abnormality 
of thrombocytes, Abnormal bleeding, Abnormality of coagulation and Abnormal 
thrombosis [15], [16]. Different types of phenotypic abnormalities are represented 
within these subclasses that are particularly relevant for BPDs, including 
morphological, cellular, physiological and laboratory-based functional abnormalities. 
Similarity values between terms and between sets of terms can be calculated, 
allowing computational comparison between patients, between patients and 
diseases and between patients and animal models, for example. We have used 
HPO to annotate approximately 1,000 cases with BPDs [17] and have shown how 
they can be automatically clustered and compared with annotations for diseases in 
the rare disease database Orphanet [18]. We have also used HPO-based statistical 
and computational methods to identify novel BPDs, including the above-mentioned  
syndrome caused by a gain-of-function variant in the universal tyrosine kinase SRC 
[13], and macrothrombocytopenia and deafness caused by gain-of-function variants 
in DIAPH1 [19]. Further on, we describe how HPO can be used for variant 
prioritisation in a diagnostic setting. 
 
Prioritisation of genetic variants  
A typical HTS experiment, even if limited to a few dozen genes, will typically result 
in hundreds or thousands of variant calls per individual, depending on the ancestry 
of the patient. The vast majority of pathogenic variants are kept at low allele 
frequency by negative selection, and therefore it is important to annotate variants by 
their population allele frequency. The largest and most widely used databases of 
variant allele frequencies include 1000 Genomes (2,504 individuals by low-depth 
WGS), UK10K (4,732 individuals by low-depth WES and 3,621 individuals by low-
depth WGS) and ExAC (60,706 individuals by WES as part of various disease-
specific and population genetic studies). These databases allow filtering or down-
weighting of variants above particular allele frequency thresholds, but the vast 
majority of rare variants, even those absent entirely from these databases, are not 
relevant to rare disease. A consequence of this is that longer genes such as VWF 
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tend to harbour more rare variants than shorter genes such as GP1BB and this 
should be kept in mind when assessing a particular variant’s relevance to a disease. 
 
Variants also need to be annotated according to their predicted consequences, 
particularly with respect to gene transcripts (e.g., missense, frameshift, intronic, 5’ 
untranslated region variant), and this is typically achieved using the Variant Effect 
Predictor (VEP) [20], which estimates consequences using data from Ensembl and 
other sources. Given that genes on Ensembl tend to have a large number of 
transcripts of which only some are relevant to a particular disease (e.g. those 
transcribed in the megakaryocyte for BPDs), it is important to take into account the 
specific transcripts against which each annotation is made. To this end, the 
ThromboGenomics gathered input from experts in different BPDs to select the 
relevant transcript for each gene.  
 
It is also essential to annotate variants against databases of variants already 
implicated in rare diseases. Unfortunately, variants identified through rare disease 
research over the last few decades and published in scientific journals have not 
been systematically entered into publicly accessible databases, and this has 
allowed commercial curators to extract information from the literature and re-sell it 
in a structured form for a fee. The most widely used commercial database of 
published variants is the Human Gene Mutation Database (HGMD), which classifies 
variants according to a curator’s assessment of the evidence presented in the 
relevant publications. Recently, the National Center for Biotechnology Information 
has released the online ClinVar database of variant interpretations for reported 
conditions [21], which accepts electronic submissions from clinical testing 
laboratories, research laboratories and other groups. ClinVar aggregates 
interpretations for a particular variant and condition into a single record, which is 
given an overall level of clinical significance. Due to the different sources for these 
two databases, the level of overlap is rather low and there is often disagreement in 
the purported pathogenicity between the two databases (Figure 1). 
 
One of the main pitfalls of these databases is that they are contaminated with 
benign variants incorrectly labelled pathogenic. Sanger sequencing studies of single 
genes in the past typically checked whether putative disease-causing variants were 
absent from small groups of healthy controls, often containing as few as 100 
individuals. For example, the variant in MYH9 encoding p.S1114P is labelled in the 
HGMD database as a disease-causing mutation for Alport syndrome with 
macrothrombocytopenia based on a report from 2001 in which a large group of 
families suspected of having MYH9-related disorder were Sanger sequenced for 
variants in MYH9 [22]. ClinVar reports this variant as having ‘Conflicting 
interpretations of pathogenicity’ as the variant has an allele frequency of 1 per 2,000 
non-Finnish Europeans in ExAC. Moreover, recently the French MYH9 network 
found this variant to be in linkage with another variant encoding p.D1424N, which 
had previously been shown to be pathogenic [23], suggesting p.S1114P was a red 
herring. Repeat submission to variant interpretation databases of incorrectly 
labelled pathogenic variants that are observed by chance in patients with a 
matching phenotype can result in a feedback loop that inflates confidence in variant 
pathogenicity. One of the tasks of the ClinGen initiative from the National Institutes 
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of Health is to organise arbitration on the clinical significance of variants with 
conflicting interpretations or with unknown significance [24]. However, arbitration 
can be compromised by a lack of reliable data acquired alongside the variant and 
phenotype submissions. For example, there is currently no mechanism in place to 
detect repeat submission of a variant from the same patient or of close relatives by 
different submitters and this can distort the evidence supporting an association 
between a variant and a particular phenotype. A possible method to tackle this 
problem would be to facilitate and encourage submission of a non-identifiable 
genetic fingerprint of each patient alongside the putative pathogenic variant. Such a 
fingerprint could be a set of genotypes at a limited set of common single nucleotide 
polymorphisms, or a projection of a standard set of genotypes onto a few principal 
components with pre-determined loadings. Disease-focused databases, such as 
the European Association for Haemophilia and Allied Disorders (EAHAD) 
coagulation factor variant databases for VWF, F7, F8 and F9, tend to be more 
dependable that general databases as they are grounded on expert knowledge and 
specific measurements of coagulation factor levels, reducing the risk of erroneous 
entries. However, for most BPDs, such databases do not exist. 
 
While the variant annotations described above are required for weighting or 
shortlisting variants for consideration, they cannot on their own provide a direct 
diagnostic answer because they need to be assessed in the context of a patient’s 
phenotype. The ThromboGenomics consortium reported that after stringent variant 
filtering, there remained more than 5 candidate variants on average per patient. As 
we describe below, variant classification for reporting is typically done at this stage 
by a dedicated multidisciplinary team. However, this process can be supported by 
computational methods that compare the HPO-coded phenotype of the patient with 
the canonical HPO-coded phenotype of each disease linked to the genes that 
harbour the variants. The ThromboGenomics consortium coded each BPD with a 
set of characteristic HPO terms and then showed that in 85% of cases (93/109), the 
correct variant could be identified by automated comparison of HPO phenotypes. 
For example, a patient coded with Decreased platelet glycoprotein lb-IX-V, 
Increased mean platelet volume, Abnormal platelet morphology, Thrombocytopenia, 
Abnormality of leukocytes, Hearing impairment and Coronary artery disease was 
sequenced and had candidate rare variants in F5, PLA2G4A, VWF and GP1BB. 
Despite atypical presence of Hearing impairment and the rather common phenotype 
Coronary artery disease, the homozygous variant in GP1BB was ranked highest 
because it was linked to Bernard-Soulier syndrome (BSS), which was coded with a 
similar phenotype, which comprised the terms Abnormal bleeding, Decreased 
platelet glycoprotein Ib-IX-V, Impaired ristocetin-induced platelet aggregation, 
Increased mean platelet volume and Thrombocytopenia. 
 
Classifying and reporting variants 
The generation of clinical reports of variants identified by HTS for feedback to 
clinicians and patients should only be performed for variants affecting Tier 1 genes 
(established BPD genes). HTS-based platforms can adapt fairly easily to emerging 
evidence supporting the addition of new genes to the Tier 1 list. However, the 
implementation of HTS approaches in clinical genetic testing raises new challenges 
in variant interpretation. The average patient screened by the ThromboGenomics 
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platform has a mean of 5 candidate variants in BPD genes after filtering and 
therefore caution in the interpretation of these variants is important. A 
multidisciplinary team (MDT) comprising a geneticist, a clinician, a bioinformatician 
and a study coordinator produce the reports after classifying the variants. 
Guidelines for the interpretation and classification of gene variants have been 
suggested by the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology [25] and similar recommendations have been 
formulated by EuroGentest and the European Society of Human Genetics [26]. 
Guidelines propose that variants are classified using standard terminology: the 
terms ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and 
‘benign’ should be used to describe variants identified in patients with rare 
hereditary disorders. These variants can have a ‘full contribution’ or ‘partial 
contribution’ to the phenotype. If a disease is recessive, a homozygous variant has 
a full contribution to the phenotype while compound heterozygous variants each 
have a partial contribution. In addition, this terminology can also be used when one 
variant cannot fully explain the entire clinical phenotype. For example, a patient with 
severe bleeding symptoms and mildly reduced FXI levels (by about 35%) received a 
report in which the heterozygous variant in F11 had been assigned the label 
‘pathogenic’ with a ‘partial contribution’ to the phenotype. This was because the 
specific variant had been shown previously to result in low FXI levels but it could 
not, on its own, cause severe bleeding. Thus, in this patient, a second unknown 
gene defect probably exists. For a variant to be considered ‘pathogenic’, it must 
have been described in at least three unrelated families with similar phenotypes. 
Variants can be labelled ‘likely pathogenic’ if they are found in a patient with a 
phenotype that is consistent with a defect in the gene it is found in and that variant 
has a low frequency (or is absent) in control databases (these databases are 
discussed in the next part). A ‘variant of uncertain significance’ (VUS) cannot be 
ruled out to play a role in disease but its consequence is too uncertain to label it 
‘pathogenic’ or ‘likely pathogenic’ based on the information available to the MDT. It 
is nevertheless worthwhile to keep a record of VUS because as more controls and 
patients are sequenced, new evidence can help reclassify VUS as ‘likely 
pathogenic’ or ‘likely benign’. Information on the ethnicity of patients should also be 
recorded because variants can be common among particular ethnic groups but rare 
in the reference control databases, which tend to have a bias towards individuals 
with European ancestry. However, it is not advisable to report VUS or benign 
variants back to clinicians and patients. 
 
Novel modes of inheritance 
Table 1 reports the modes of inheritance (MOI) for the different BPDs. It is becoming 
apparent that certain genes are involved in both recessive and dominant disorders. 
This was first shown in relation to  ITGA2B and ITGB3, which was originally 
reported to harbour variants responsible for Glanzmann Thrombasthenia (GT), an 
autosomal recessive bleeding disorder characterised by failure of platelet 
aggregation with typically normal platelet count [27]. Specific variants in these 
genes were subsequently shown to lead to a dominant disorder characterised by 
macrothrombocytopenia and very mild platelet dysfunction [28], [29], [30], [31], [32], 
[33], [34]. Similarly, BSS is an autosomal recessive bleeding disorder caused by a 
deficiency of the platelet membrane von Willebrand factor receptor due to variants 
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in the GP1BA, GP1BB or GP9 genes [35]. BSS patients have very large platelets 
with thrombocytopenia and platelet dysfunction. A dominant variant in GP1BA 
(referred to as the Bolzano variant [36]) results in mild macrothrombocytopenia while 
a similar platelet phenotype was recently described for patients with dominant 
variants in GP1BB [37]. A recent study of Gray Platelet Syndrome (GPS) patients 
with recessive variants in NBEAL2 found milder platelet GPS-like phenotypes in the 
obligate carriers [38]. Both dominant-negative, high-impact variants in GFI1B 
located in the region coding the zinc fingers [39], [40] and hypomorphic biallelic 
GFI1B variants result in thrombocytopenia with reduced numbers of platelet 
granules [41]. A very similar finding was made for Paris-Trousseau 
thrombocytopenia, which is mostly the result of a FLI1 deletion (11q deletion) or 
high impact variants on FLI1, but it was recently shown that homozygous or 
compound heterozygous missense variants in the DNA-binding domain of FLI1 can 
also cause this disease [42]. The discovery of novel MOI for established BPD genes 
raises the question of how best to classify diseases in relation to genes, a topic of 
interest for the SSC on GinTH.  
 
In addition to dominant versus recessive MOI, there is emerging evidence that 
combinations of variants in two different BPD genes can result in phenotypes that 
are absent or much less severe when only one of the variants is present. Variants in 
P2RY12 can result in a recessive bleeding disorder characterised by a platelet ADP 
aggregation defect while heterozygous carriers are not affected [43].  Interestingly, 
two studies have now reported a heterozygous variant in P2RY12 in a patient with 
an aggregation defect and bleeding history much more severe than found for other 
obligate carriers [44], [45]. In these cases, an additional defect would be expected 
and indeed this was shown to be the case in one of these patients, who had a 
second pathogenic variant in VWF [44]. Another example of possible digenic 
inheritance was described recently in relation to a pedigree in which members with 
haemophilia A bleed more severely if they also carry a common variant in PTGS1 
(ExAC allele frequency of 14% in Africans) than if they dio not [46]. The difficulty 
with generating a conclusive diagnosis in cases with digenic inheritance is the 
sparsity of cases with similar combinatorial defects to compare against, but it is 
nevertheless a possibility that may need to be considered during deliberation by 
MDTs. 
 
Whole-genome DNA sequencing 
The major challenge ahead will be the analysis of the regulatory regions of the 
genome. Currently, there is a scarcity of large-scale population allele frequency 
databases spanning the entire genome. Recently, a group from Human Longevity 
Inc reported their results from analysing 10,000 deeply sequenced whole genomes 
[47] but the variant calls are available only through a restricted browser-based 
search function. The preliminary release of the gnomAD database (126,216 
individuals by WES and 15,136 by WGS, but including individuals in ExAC) can at 
present only be accessed using a web browser but it will eventually be made 
available for download. Once population allele frequencies derived from large 
numbers of individuals become available, it will remain challenging to assess 
pathogenicity of non-exonic rare variants. First, they are far more numerous than 
exonic rare variants because exons cover only 1/50th of the genome and because 
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non-exonic regions tend to be less conserved than exonic regions and thus tend to 
harbour a higher density of rare variants. Second, as they do not alter protein 
sequence, it is often unclear which regulatory pathway they disrupt, if any. To tackle 
these difficulties, it will be necessary, initially, to focus attention on carefully 
selected segments of the non-exonic space, such as those believed to play 
important roles in gene expression regulation, including promoter and enhancer 
regions. 
 
Within the field of BPDs specifically, various strategies could be followed to identify 
such regions. They could be identified using the ENCODE database of active 
regulatory regions and the binding sites of relevant transcription factors (e.g. 
GATA1, FLI1, ETS1, NFE2 and GATA2) in the megakaryocytic cell line K562. 
Chromatin immunoprecipitation (ChIP) sequencing data from primary 
megakaryocytes are also available for GATA1, GATA2, RUNX1, FLI1, and SCL [48]. 
A large genome-wide association study of 173,480 European-ancestry participants 
recently identified hundreds of low frequency (<5%) and rare (<1%) variants 
associated with full blood count parameters, including platelet volume, count, crit 
(total platelet mass) and distribution width [49]. Many of these variants are located in 
non-coding regions that are likely to play a role in the formation or clearance of 
platelets and, as such, they are regions of potential interest in the context of BPD 
patients. The same applies to variants associated with gene expression of nearby 
genes (expression quantitative trait loci (eQTL)) in platelets. Studies of the 
epigenomic landscape of the megakaryocyte have recently been conducted, 
revealing areas that are likely to be enhancers, for example (Petersen et al., under 
review). 
 
How large is the non-exonic space that is potentially of relevance to BPDs? To try 
to answer this question, we have combined information from genetic association 
studies, studies of transcription factor binding sites and epigenomic studies to 
identify non-exonic regions that may play a role in the aetiology of BPDs. Each base 
in the genome was labelled according to whether a particular signature was 
switched on. These signatures indicate features such as proximity to a locus in 
population association with platelet parameters measured by a haematology 
analyser, or presence of a peak for a particular transcription factor as measured by 
ChIP sequencing in megakaryocytes, for example. In total, we identified 54Mb of 
non-exonic regions with a regulatory signature suggestive of a functional role in 
megakaryocytes. This is comparable to the exonic space across all protein-coding 
genes. Most of the non-exonic segments are regions of open chromatin that are 
also marked as enhancers, promoters or binding sites for the structural protein 
CTCF (Figure 2, bottom panel). In contrast, the regions with the densest signatures, 
i.e. those in which many indicators of functional relevance are present, tend to 
cover a very small fraction of the genome (Figure 2, top panel). One of the densest 
signatures has all features except association with platelet crit, presence of a 
nearby eQTL and enhancer (row five in Figure 2) and is found solely in the vicinity of 
GP1BB. Interestingly, a BPD-causing non-coding variant has been reported in a 
BSS patient with a missense variant in GP1BB and another variant in the opposite 
haplotype of the GP1BB promoter that resulted in reduced GATA1-binding [50]. As 
our knowledge of the regulatory role of non-coding regions of the genome and the 
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impact of rare variants therein becomes clearer, it will become feasible to 
incorporate such variants in the diagnostic work-up. 
 
There are also technical advantages to using WGS that will improve diagnostic yield 
as WGS becomes commonplace. In general, WGS is a more sensitive method than 
targeted sequencing for detecting structural variants such as large deletions, 
insertions, inversions, tandem repeat expansions and complex rearrangements. It 
may be that a certain fraction of undiagnosed patients have variants that affect 
known genes but in ways that require WGS to be adequately detected. Finally, 
although current sequencing read lengths are typically 100-150bp, emerging long-
read sequencing technology is capable of generating reads tens of thousands of bp 
long. In addition to improving power to detect structural variants, long reads 
facilitate phasing of rare variants affecting the same region. For recessive diseases, 
this will reduce the need for parental samples to ascertain whether rare variants are 
in trans in the offspring. 
 
Concluding remarks 
Intensive research activity in rare diseases continues to reveal new genes and 
regulatory regions of potential importance as well as novel modes of inheritance for 
established genes. As the evidence supporting new aetiologies accumulates and 
new findings gain Tier 1 status, diagnostic practice needs to react to these 
developments. The most advanced assays in routine use today target a relatively 
small, pre-determined part of the human genome, but can be re-versioned regularly. 
Over the next few years, however, WGS will replace targeted platforms universally. 
The complexity and size of the sequencing data, the phenotypic data and the 
breadth of potential aetiologies that must be accounted for, along with the multiple 
layers of genomic information needed to interpret the possible effects of non-coding 
variants, require changes in the diagnostic process. Multidisciplinary teams 
composed of clinicians, geneticists and bioinformaticians need to work together to 
provide a rapid yet reliable service that utilises all the evidence available effectively. 
The careful aggregation of clinical and genetic data from across the globe in freely 
accessible databases will prove essential to properly assess the ever-changing 
evidence for pathogenicity of particular variants. We are amidst a transition of 
clinical genetics into a globally networked, computer-aided and multidisciplinary 
discipline that will increase diagnostic yield and improve patient care substantially. 
 
Figure legends 
Figure 1: Venn diagram illustrating the degree of overlap between pathogenic (DM) 
or likely pathogenic (DM?) variants in HGMD and variants in ClinVar. The overlap is 
broken down into four categories, according to whether variants are labelled 
pathogenic in ClinVar, have conflicting interpretations, are labelled benign, or lack 
any interpretations. We thank Steven Harrison for kindly providing the data for this 
figure, which are accurate as of August 2016. 
 
Figure 2: Each column in the grids represents a regulatory feature, which may be 
part of a regulatory signature (blue) or absent from it (grey) at any location in the 
genome. PCT, PDW, PLT, MPV: proximity of a variant in population association with 
platelet crit, platelet distribution width, platelet count or mean platelet volume, 
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respectively; eQTL: proximity of a variant associated with expression of a nearby 
gene in platelets (data not published); GATA1, GATA2, FLI1, RUNX1, SCL, MEIS1: 
transcription factor binding sites in MKs as identified by ChIP sequencing; CTCF: 
binding site for the transcription repressor CTCF in MKs; Enhancer, Promoter: 
region assigned as having enhancer or promoter activity, respectively, in Petersen 
et al.; ATAC: regions of accessible chromatin identified using Assay for 
Transposase-Accessible Chromatin sequencing of DNA from MKs (data not 
published). The top grid and associated bar plot show the signatures with the 
highest number of regulatory features and the number of bases in the genome in 
which those signatures are present. The bottom grid and associated bar plot show 
the signatures which cover the largest fractions of the genome.  
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